Clinical Trial Update: Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial investigating lenalidomide and temsirolimus in relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma across Phase 1 and Phase 2; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: AIDS-Related Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-10-16